Six leading institutions have formed an alliance designed to accelerate the translation of academic research into usable medicines and therapies. The six include:
- The Centre for Drug Research and Development (CDRD), Canada
- Lead Discovery Centre (LDC), Germany
- The Scripps Research Institute, Scripps Florida, United States
- The Centre for Drug Design and Discovery (CD3), KU Leuven R&D, Belgium
- Medical Research Council (MRC) Technology, United Kingdom
- Cancer Research Technology (CRT), United Kingdom
The six organizations plan to facilitate international cooperation, develop standards and performance measurements, share best practices, expertise and resources, and collaborate on drug development projects. Ultimately , they will work together to improve the conversion of global early-stage research into much-needed new therapies. Currently, they have a portfolio of more than 165 innovative therapeutic projects targeting significant unmet medical needs.
This is yet another shot at improving translational activities. Lack of good translation seems to be a popular whipping boy as to one major element that plaques the current pharma model. We'll have to see if efforts by this group or others like NIH really have a winning effect.